Rossella Paolini

List of Publications by Year
in descending order

93	3,155	147801	175258
papers	citations	31 h-index	52 g-index

94	94	94	4507
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Impact on NK cell functions of acute versus chronic exposure to extracellular vesicleâ€associated MICA: Dual role in cancer immunosurveillance. Journal of Extracellular Vesicles, 2022, 11, e12176.	12.2	22
2	NK Cells and Other Cytotoxic Innate Lymphocytes in Colorectal Cancer Progression and Metastasis. International Journal of Molecular Sciences, 2022, 23, 7859.	4.1	10
3	Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group. Hematological Oncology, 2021, 39, 326-335.	1.7	8
4	Cereblon regulates NK cell cytotoxicity and migration via Rac1 activation. European Journal of Immunology, 2021, 51, 2607-2617.	2.9	5
5	Immunomodulatory effect of NEDD8-activating enzyme inhibition in Multiple Myeloma: upregulation of NKG2D ligands and sensitization to Natural Killer cell recognition. Cell Death and Disease, 2021, 12, 836.	6.3	13
6	Immune complexes exposed on mast cellâ€derived nanovesicles amplify allergic inflammation. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 1260-1263.	5.7	18
7	SAMHD1 phosphorylation and cytoplasmic relocalization after human cytomegalovirus infection limits its antiviral activity. PLoS Pathogens, 2020, 16, e1008855.	4.7	12
8	FcÎµRI Signaling in the Modulation of Allergic Response: Role of Mast Cell-Derived Exosomes. International Journal of Molecular Sciences, 2020, 21, 5464.	4.1	21
9	Bone Marrow Stromal Cell-Derived IL-8 Upregulates PVR Expression on Multiple Myeloma Cells via NF-kB Transcription Factor. Cancers, 2020, 12, 440.	3.7	21
10	CD155: A Multi-Functional Molecule in Tumor Progression. International Journal of Molecular Sciences, 2020, 21, 922.	4.1	58
11	Clinical Characteristics and Outcome of West Nile Virus Infection in Patients with Lymphoid Neoplasms: An Italian Multicentre Study. HemaSphere, 2020, 4, e395.	2.7	4
12	Post-translational Mechanisms Regulating NK Cell Activating Receptors and Their Ligands in Cancer: Potential Targets for Therapeutic Intervention. Frontiers in Immunology, 2019, 10, 2557.	4.8	20
13	Activation of liver X receptor upâ€regulates the expression of the NKG2D ligands MICA and MICB in multiple myeloma through different molecular mechanisms. FASEB Journal, 2019, 33, 9489-9504.	0.5	19
14	The Ubiquitinâ€proteasome pathway regulates Nectin2/CD112 expression and impairs NK cell recognition and killing. European Journal of Immunology, 2019, 49, 873-883.	2.9	28
15	The homeobox transcription factor MEIS2 is a regulator of cancer cell survival and IMiDs activity in Multiple Myeloma: modulation by Bromodomain and Extra-Terminal (BET) protein inhibitors. Cell Death and Disease, 2019, 10, 324.	6.3	11
16	Lenalidomide in Pretreated Patients with Diffuse Large Bâ€Cell Lymphoma: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice. Oncologist, 2019, 24, 1246-1252.	3.7	10
17	Translating the anti-myeloma activity of Natural Killer cells into clinical application. Cancer Treatment Reviews, 2018, 70, 255-264.	7.7	28
18	Rituximab, bendamustine and cytarabine (Râ€BAC) in patients with relapsedâ€refractory aggressive Bâ€cell lymphoma. American Journal of Hematology, 2018, 93, E386-E389.	4.1	4

#	Article	IF	Citations
19	NKG2D and Its Ligands: â€œOne for All, All for Oneâ€• Frontiers in Immunology, 2018, 9, 476.	4.8	165
20	Italian real life experience with ibrutinib: results of a large observational study on 77 relapsed/refractory mantle cell lymphoma. Oncotarget, 2018, 9, 23443-23450.	1.8	12
21	Abnormal regulation of BCR signalling by c-Cbl in chronic lymphocytic leukaemia. Oncotarget, 2018, 9, 32219-32231.	1.8	6
22	Genotoxic stress modulates the release of exosomes from multiple myeloma cells capable of activating NK cell cytokine production: Role of HSP70/TLR2/NF-kB axis. OncoImmunology, 2017, 6, e1279372.	4.6	100
23	p38 MAPK differentially controls NK activating ligands at transcriptional and post-transcriptional level on multiple myeloma cells. OncoImmunology, 2017, 6, e1264564.	4.6	29
24	Plasma matrix metalloprotease 9 correlates with blood lymphocytosis, leukemic cell invasiveness, and prognosis in B-cell chronic lymphocytic leukemia. Tumor Biology, 2017, 39, 101042831769432.	1.8	10
25	Obinutuzumab-mediated high-affinity ligation of FcÎ³RIIIA/CD16 primes NK cells for IFNÎ³ production. OncoImmunology, 2017, 6, e1290037.	4.6	39
26	3D Microfluidic model for evaluating immunotherapy efficacy by tracking dendritic cell behaviour toward tumor cells. Scientific Reports, 2017, 7, 1093.	3.3	130
27	Epstein-Barr Virusâ€“Positive Mucocutaneous Ulcer Mimicking Rectal Carcinoma at 18F-FDG PET/CT. Clinical Nuclear Medicine, 2017, 42, 645-646.	1.3	7
28	Antiplatelet therapy in patients with glucose-6-phosphate dehydrogenases deficiency after percutaneous coronary intervention: A reappraisal for clinical and interventional cardiologists. Cardiovascular Revascularization Medicine, 2017, 18, 226-229.	0.8	4
29	Innate immune activating ligand SUMOylation affects tumor cell recognition by NK cells. Scientific Reports, 2017, 7, 10445.	3.3	29
30	Regulation of NKG2D-Dependent NK Cell Functions: The Yin and the Yang of Receptor Endocytosis. International Journal of Molecular Sciences, 2017, 18, 1677.	4.1	71
31	Targeted therapy in severe asthma today: focus on immunoglobulin E. Drug Design, Development and Therapy, 2017, Volume 11, 1979-1987.	4.3	38
32	Ubiquitin and ubiquitin-like modifiers modulate NK cell-mediated recognition and killing of damaged cells. AIMS Allergy and Immunology, 2017, 1, 164-180.	0.5	0
33	Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay. Journal of Hematology and Oncology, 2016, 9, 134.	17.0	72
34	Regulation of NKG2D Expression and Signaling by Endocytosis. Trends in Immunology, 2016, 37, 790-802.	6.8	46
35	Complex chromosomal rearrangements leading to <scp>MECOM</scp> overexpression are recurrent in myeloid malignancies with various 3q abnormalities. Genes Chromosomes and Cancer, 2016, 55, 375-388.	2.8	5
36	Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a Phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia. Haematologica, 2015, 100, 511-516.	3.5	42

#	Article	IF	Citations
37	Nitric oxide donors increase PVR/CD155 DNAM-1 ligand expression in multiple myeloma cells: role of DNA damage response activation. BMC Cancer, 2015, 15, 17.	2.6	54
38	Genotoxic Stress Induces Senescence-Associated ADAM10-Dependent Release of NKG2D MIC Ligands in Multiple Myeloma Cells. Journal of Immunology, 2015, 195, 736-748.	0.8	85
39	Response criteria for malignant lymphoma. Nuclear Medicine Communications, 2015, 36, 398-405.	1.1	1
40	NK cells and interferons. Cytokine and Growth Factor Reviews, 2015, 26, 113-120.	7.2	110
41	Ubiquitin-dependent endocytosis of NKG2D-DAP10 receptor complexes activates signaling and functions in human NK cells. Science Signaling, 2015, 8, ra108.	3.6	50
42	Anti-CD20 Therapy Acts via FcÎ³RIIIA to Diminish Responsiveness of Human Natural Killer Cells. Cancer Research, 2015, 75, 4097-4108.	0.9	46
43	The IMiDs targets IKZF-1/3 and IRF4 as novel negative regulators of NK cell-activating ligands expression in multiple myeloma. Oncotarget, 2015, 6, 23609-23630.	1.8	78
44	Clinical significance of LAIR1 (CD305) as assessed by flow cytometry in a prospective series of patients with chronic lymphocytic leukemia. Haematologica, 2014, 99, 881-887.	3.5	32
45	Regulation of Fc Receptor Endocytic Trafficking by Ubiquitination. Frontiers in Immunology, 2014, 5, 449.	4.8	37
46	câ€Cbl regulates MICAâ€•but not ULBP2â€•induced NKG2D downâ€•modulation in human NK cells. European Journal of Immunology, 2014, 44, 2761-2770.	2.9	35
47	The combination of rituximab, bendamustine, and cytarabine for heavily pretreated relapsed/refractory cytogenetically highâ€risk patients with chronic lymphocytic leukemia. American Journal of Hematology, 2013, 88, 289-293.	4.1	19
48	Combination of Rituximab, Bendamustine, and Cytarabine for Patients With Mantle-Cell Non-Hodgkin Lymphoma Ineligible for Intensive Regimens or Autologous Transplantation. Journal of Clinical Oncology, 2013, 31, 1442-1449.	1.6	167
49	Bendamustine in chronic lymphocytic leukemia: Outcome according to different clinical and biological prognostic factors in the everyday clinical practice. American Journal of Hematology, 2013, 88, 955-960.	4.1	14
50	PIP2-dependent regulation of Munc13-4 endocytic recycling: impact on the cytolytic secretory pathway. Blood, 2012, 119, 2252-2262.	1.4	27
51	Sykâ€dependent regulation of <scp>H</scp>rs phosphorylation and ubiquitination upon <scp>F</scp>cÎµ<scp>RI</scp> engagement: Impact on <scp>H</scp>rs membrane/cytosol localization. European Journal of Immunology, 2012, 42, 2744-2753.	2.9	16
52	Clinical Relevance of the Dose of Cytarabine in the Upfront Treatment of Primary CNS Lymphomas with Methotrexateâ€Cytarabine Combination. Oncologist, 2011, 16, 336-341.	3.7	30
53	Cbl Family Proteins: Balancing FcεRI-Mediated Mast Cell and Basophil Activation. International Archives of Allergy and Immunology, 2011, 156, 16-26.	2.1	7
54	Autoimmune hemolytic anemia in patients with chronic lymphocytic leukemia is associated with IgVH status. Haematologica, 2010, 95, 1230-1232.	3.5	33

#	Article	IF	Citations
55	Attenuation of PI3K/Akt-Mediated Tumorigenic Signals through PTEN Activation by DNA Vaccine-Induced Anti-ErbB2 Antibodies. Journal of Immunology, 2010, 184, 4170-4177.	0.8	19
56	Ubiquitination and endocytosis of the high affinity receptor for IgE. Molecular Immunology, 2010, 47, 2427-2434.	2.2	23
57	Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies. Thrombosis and Haemostasis, 2009, 101, 233-238.	3.4	85
58	Lipid Raft-Dependent FcÎµRI Ubiquitination Regulates Receptor Endocytosis through the Action of Ubiquitin Binding Adaptors. PLoS ONE, 2009, 4, e5604.	2.5	28
59	Consolidation treatment with rituximab induces complete and persistent remission of mixed type Evans syndrome. Blood Coagulation and Fibrinolysis, 2008, 19, 315-318.	1.0	4
60	The Adaptor Molecule CIN85 Regulates Syk Tyrosine Kinase Level by Activating the Ubiquitin-Proteasome Degradation Pathway. Journal of Immunology, 2007, 179, 2089-2096.	0.8	20
61	Negative signals from FcÎµRI engagement attenuate mast cell functions. Archivum Immunologiae Et Therapiae Experimentalis, 2007, 55, 219-229.	2.3	17
62	Hyperthyroidism as a Cause of Pulmonary Arterial Hypertension: A Prospective Study. Angiology, 2006, 57, 600-606.	1.8	44
63	CIN85 Regulates the Ligand-Dependent Endocytosis of the IgE Receptor: A New Molecular Mechanism to Dampen Mast Cell Function. Journal of Immunology, 2005, 175, 4208-4216.	0.8	45
64	Pulmonary Hypertension and Systemic Diseases. Inflammation and Allergy: Drug Targets, 2004, 3, 459-467.	3.1	2
65	Defective expression of the T-cell receptor-CD3 Î¶ chain in T-cell acute lymphoblastic leukaemia. British Journal of Haematology, 2003, 120, 201-208.	2.5	18
66	Spontaneous evolution of essential thrombocythaemia into acute megakaryoblastic leukaemia with trisomy 8, trisomy 21 and cutaneous involvement. European Journal of Haematology, 2003, 71, 466-469.	2.2	7
67	Activation of Syk Tyrosine Kinase Is Required for c-Cbl-mediated Ubiquitination of FcÎµRI and Syk in RBL Cells. Journal of Biological Chemistry, 2002, 277, 36940-36947.	3.4	73
68	Hashimoto's Thyroiditis and Graves' Disease Associated with Retroperitoneal Fibrosis. Thyroid, 2002, 12, 829-831.	4.5	28
69	Ubiquitination and degradation of Syk and ZAP-70 protein tyrosine kinases in human NK cells upon CD16 engagement. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 9611-9616.	7.1	52
70	Co-existence of cutaneous T-cell lymphoma and B hairy cell leukemia. American Journal of Hematology, 2000, 64, 197-202.	4.1	13
71	Acute myocardial infarction during treatment with intravenous immunoglobulin for idiopathic thrombocytopenic purpura (ITP). American Journal of Hematology, 2000, 65, 177-178.	4.1	36
72	Cutting Edge: Functional Role for Proline-Rich Tyrosine Kinase 2 in NK Cell-Mediated Natural Cytotoxicity. Journal of Immunology, 2000, 164, 2272-2276.	0.8	50

#	Article	IF	Citations
73	Tyrosine kinase-dependent ubiquitination of CD16 Î¶ subunit in human NK cells following receptor engagement. European Journal of Immunology, 1999, 29, 3179-3187.	2.9	21
74	The Release of Tissue Factor Pathway Inhibitor and Platelet Factor 4 After Heparin Injection in Patients with Thrombocytosis. Hematology, 1997, 2, 235-241.	1.5	0
75	Splenomegaly as the First Manifestation of Thyroid Cancer Metastases. Tumori, 1997, 83, 779-782.	1.1	13
76	B Non-Hodgkin's Lymphoma in a Haemophilia Patient with Idiopathic CD4+ T-lymphocytopenia. Leukemia and Lymphoma, 1996, 21, 177-180.	1.3	11
77	Persistence of Tyrosine-phosphorylated FcÎµRI in Deactivated Cells. Journal of Biological Chemistry, 1996, 271, 15987-15992.	3.4	13
78	Syk-dependent Phosphorylation of Shc. Journal of Biological Chemistry, 1996, 271, 16268-16272.	3.4	117
79	Perinatal Intracranial Hemorrhage as First Manifestation of Congenital Hypofibrinogenemia. Clinical and Applied Thrombosis/Hemostasis, 1996, 2, 60-63.	1.7	2
80	Remission of leukaemic meningitis after fludarabine. Lancet, The, 1995, 346, 972.	13.7	8
81	Kinase Activation through the High-Affinity Receptor for Immunoglobulin E. ImmunoMethods, 1994, 4, 35-40.	0.8	13
82	Anti-hepatitis C virus serology in patients affected with congenital coagulation defects: A comparative study using three second generation ELISA tests. Transfusion Science, 1994, 15, 303-311.	0.6	2
83	Recent Advances in the Field of High Affinity IgE Receptors: the Connection to Signal Transduction. , 1993, , 435-440.		0
84	Interaction between Histidine-Rich Glycoprotein and Platelet Factor 4 with Dermatan Sulfate and Low-Molecular-Weight Dermatan Sulfate. Angiology, 1992, 43, 59-62.	1.8	23
85	Heparin released platelet factor 4 in uncomplicated type 1 diabetes mellitus. Thrombosis Research, 1991, 62, 603-604.	1.7	0
86	Phosphorylation and dephosphorylation of the high-affinity receptor for immunoglobulin E immediately after receptor engagement and disengagement. Nature, 1991, 353, 855-858.	27.8	280
87	Adhesion and activation molecules expressed by human natural killer cells. Cytotechnology, 1991, 5, 117-121.	1.6	3
88	Modulation of CD16 Antigen on NK Cells and Granulocytes by Protein Kinase C Activators and Inhibitors1. , 1990, , 80-84.		0
89	Effects of Glycosaminoglycans and Protamine Chloridrate on Platelet Aggregation Induced by Collagen and Thrombin. Angiology, 1989, 40, 170-174.	1.8	7
90	Effects of protein kinase C (PK-C) activators and inhibitors on human large granular lymphocytes (LGL): Role of PK-C on natural killer (NK) activity. Cellular Immunology, 1989, 118, 470-481.	3.0	27

#	Article	IF	Citations
91	In vivo cadmium treatment alters natural killer activity and large granular lymphocyte number in the rat. Immunopharmacology, 1989, 18, 149-156.	2.0	38
92	Effects of cadmium on lymphocyte activation. Biochimica Et Biophysica Acta - Molecular Cell Research, 1989, 1011, 25-32.	4.1	42
93	Proliferative effects of 12-O-Tetradecanoylphorbol-13-acetate (TPA) and calcium ionophores on human large granular lymphocytes (LGL). Cellular Immunology, 1988, 113, 70-81.	3.0	12